Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Choueiri on the Utility of Belzutifan/Cabozantinib in Advanced ccRCC

October 27th 2023

Toni K. Choueiri, MD, discusses findings from the phase 2 LITESPARK-003 study of belzutifan in combination with cabozantinib for patients with advanced clear cell renal cell carcinoma.

Patient and Disease Characteristics Serve as Key Factors Behind Treatment Considerations in Advanced RCC

October 26th 2023

Vitaly Margulis, MD, expands on the factors to consider when treating patients with advanced RCC and how these could help inform the selection of immunotherapy-based combinations in the frontline setting.

Updated Data Continue to Aid IO-Based Frontline Treatment Decisions in Advanced RCC

October 24th 2023

Tian Zhang, MD, MHS, details how updated data presented at the 2023 ASCO Annual Meeting from trials such as KEYNOTE-426 and CLEAR have showed the sustained efficacy of VEGF plus immunotherapy combinations vs sunitinib in the first-line setting; discusses where the immunotherapy-only combination of ipilimumab and nivolumab fits in the frontline setting; and highlights how data from CONTACT-03 provided key insights on the use of immunotherapy in patients with advanced renal cell carcinoma after progression on a prior immune checkpoint inhibitor.

Retrospective Data Show Nephrectomy With Immune-Targeted Therapy Offers Potential PFS Benefit in Metastatic RCC

October 24th 2023

Nephrectomy with immune-targeted therapy was associated with a progression-free survival benefit compared with immunotherapy alone in patients with metastatic renal cell carcinoma.

Lenvatinib/Pembrolizumab Combo Elicits Durable Responses in Advanced ccRCC

October 23rd 2023

Lenvatinib in combination with pembrolizumab led to tumor shrinkage and duration of response benefits compared with sunitinib across subgroups of interest in patients with advanced clear cell renal cell carcinoma.

Looking at Novel Treatments in Lung and Genitourinary Cancers From ESMO 2023: Drs Janne and Bastos

October 21st 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Belzutifan Generates Superior PFS, ORR in Pretreated Advanced ccRCC

October 21st 2023

Treatment with belzutifan produced improvements in progression-free survival and objective response rate vs everolimus in patients with pretreated advanced clear cell renal cell carcinoma.

Belzutifan Plus Cabozantinib Delivers Durable Responses in ccRCC

October 21st 2023

Belzultifan in combination with cabozantinib generated durable responses independent of International Metastatic RCC Database Consortium risk category in patients with treatment-naïve clear cell renal cell carcinoma or those who had received prior immunotherapy.

Dr Hammers on a Case Presentation in Advanced RCC

October 21st 2023

Hans Hammers, MD, PhD, discusses a case presentation of a patient with advanced renal cell carcinoma.

Understanding Unprecedented Data in Genitourinary Cancers From ESMO 2023: Dr Powles

October 20th 2023

Dr Bilusic on Updates to the Urothelial Carcinoma Treatment Armamentarium

October 20th 2023

Marijo Bilusic, MD, PhD, discusses updates seen in the treatment armamentarium for patients with urothelial carcinoma, as presented at the 2023 Sylvester Annual Oncology Updates Meeting.

ESMO 2023: Experts Preview Anticipated Data Spanning Tumor Types

October 19th 2023

The 2023 ESMO Congress, which is taking place in Madrid, Spain, and will continue to be accessible online via a virtual platform, is gearing up to kick off, and the oncology community is ready to learn more about the latest data across malignancies.

Subcutaneous Nivolumab Meets PK and ORR End Points in Pretreated Advanced or Metastatic ccRCC

October 19th 2023

Treatment with subcutaneous nivolumab co-formulated with recombinant human hyaluronidase demonstrated noninferior pharmacokinetics vs intravenous nivolumab in patients with advanced or metastatic clear cell renal cell carcinoma who received prior systemic therapy.

Dr Yentz on Treatment Decisions in Favorable-Risk RCC

October 18th 2023

Sarah Elizabeth Yentz, MD, discusses treatment considerations in patients with favorable-risk renal cell carcinoma.

New Data Bring Excitement, Raise Questions in Advanced RCC

October 16th 2023

Although renal cell carcinoma remains a difficult-to-treat disease, with patients with clear cell histology experiencing a median overall survival of approximately 13 months and a 5-year overall survival rate of less than 10%, updated results from clinical trials examining emerging therapeutic strategies have spurred optimism.

State of the Science Summit - Prostate/RCC: Chaired by Marijo Bilusic, MD, PhD

October 11th 2023

State of the Science Summit - Prostate/RCC: Chaired by Marijo Bilusic, MD, PhD

Dr Choueiri on the Benefit of Ongoing Investigations in Metastatic RCC

October 7th 2023

Toni K. Choueiri, MD, discusses the benefit of ongoing investigations in metastatic, advanced renal cell carcinoma.

Dr Margulis on Patient Factors to Consider in the Treatment of RCC

September 28th 2023

Vitaly Margulis, MD, discusses significant factors and comorbidities that may affect treatment decisions for patients with renal cell carcinoma.

Dr Biachi on the Growing Treatment Landscape in HCC

September 27th 2023

Tiago Biachi, MD, PhD, discusses the growing treatment landscape for patients with hepatocellular carcinoma.

Dr. Zhang on the Selection of Immunotherapy-Based Regimens in Metastatic RCC

September 27th 2023

Tian Zhang, MD, MHS, discusses the selection of first-line immunotherapy-based treatments for patients with metastatic renal cell carcinoma.